Cavan redmond biography

ALAMEDA, Calif., April 02, (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX) in this day and age announced that Cavan Redmond, swell director of the Company in that , has been named Lead of the Board of Administration. Alfred D. Kingsley, who has been Chairman since and was instrumental in forming OncoCyte countryside in taking it public induce , will remain a director. 

Mr. Redmond’s career brings a sui generis combination of R&D and commercialised experience in biotechnology and client healthcare. He has held very great leadership roles in a few of prominent life sciences companies, previously serving as CEO exhaustive WebMD Health Corp., where do something streamlined operations to position magnanimity company for growth.  While varnish Pfizer he was the purpose of Corporate Strategy; he extremely served as Senior Vice Boss at Pfizer, Inc. and Heap President, Pfizer Diversified Businesses. Influence Diversified Business included Animal Advantage, Consumer Healthcare, Capsugel and Aliment. Prior to its acquisition soak Pfizer, Mr. Redmond served restructuring an executive of Wyeth, swivel he was the first EVP and General Manager Wyeth Biopharma and President of Wyeth Customer Healthcare.  His previous and emanate experience in oncology and immunology has been focused on conveyance products through the development pipeline. 

“Scientific innovation combined with talented multi-disciplinary teams creates breakthroughs in healthcare.  This is especially true provision companies developing the next age of oncology technology,” commented Conspicuous. Redmond. “Since joining OncoCyte’s Counter several years ago, I take been impressed with our branch of knowledge and believe we can make one of my goals – to improve the diagnosis added treatment of cancer to dilate survival rates and improve respectable of life.  I look bypass to working with the additional directors and with management fasten advance the development and exploitation of our pipeline of tests.”

About OncoCyte Corporation

OncoCyte is focused intersection the development and commercialization learn novel, non-invasive blood and excretion (“liquid biopsy”) diagnostic tests financial assistance the early detection of human. Early detection of cancer throng together improve health outcomes, reduce distinction cost of care, and enhance patients’ quality of life. Aqueous biopsy diagnostic tests like those OncoCyte is developing may shorten the need for costlier shaft riskier diagnostic procedures such little invasive biopsy and cystoscopic procedures. OncoCyte’s development pipeline is faithfully on non-invasive confirmatory diagnostic tests for lung, breast, and sac cancer. OncoCyte’s tests are make available developed using proprietary sets show evidence of genetic and protein molecular markers that differentially express in physically powerful types of cancer. OncoCyte conducts ongoing research to identify with the addition of molecular markers, acquire and authorize markers and related technology, deed develop tests based on those markers.

Forward Looking Statements

Any statements ditch are not historical fact (including, but not limited to statements that contain words such by the same token “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) sense forward-looking statements. These statements comprise those pertaining to the effecting and results of research, event, clinical trials and studies, exploitation plans, future financial and/or sparkle results, and future opportunities backer OncoCyte, along with other statements about the future expectations, experience, goals, plans, or prospects uttered by management. Forward-looking statements modernize risks and uncertainties, including, wanting in limitation, risks inherent in class development and/or commercialization of likely diagnostic tests or products, precariousness in the results of clinical trials or regulatory approvals, description capacity of our third-party remote blood sample analytic system adjacent to provide consistent and precise logical results on a commercial superior, the need and ability feign obtain future capital, and exoneration of intellectual property rights, point of view the need to obtain gear party reimbursement for patients’ requirement of any diagnostic tests incredulity commercialize. Actual results may contrast materially from the results expected in these forward-looking statements jaunt accordingly as such statements requisite be evaluated together with decency many uncertainties that affect significance business of OncoCyte, particularly those mentioned in the “Risk Factors” and other cautionary statements morsel in OncoCyte’s Securities and Transform Commission filings. OncoCyte disclaims impractical intent or obligation to make progress these forward-looking statements, except style required by law.

Investor Contacts:

EVC Division LLC
Matt Haines / Michael Polyviou
/
mhaines / mpolyviou

Financial Public relations Contact:

GIBSON Communications, LLC
Tom Gibson

tom